Literature DB >> 7484833

Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study).

T Gotoh1, T Kuroda, M Yamasawa, M Nishinaga, T Mitsuhashi, Y Seino, N Nagoh, K Kayaba, S Yamada, H Matsuo.   

Abstract

An elevated serum level of lipoprotein(a) (Lp[a]) may be an independent risk factor for atherosclerotic disease, but the relation of Lp(a) to aortic valve (AV) sclerosis has not been determined. We measured serum concentrations of Lp(a) and investigated their relation to the presence of echocardiographic AV sclerosis in residents of a rural village in Japan. We measured serum Lp(a) levels in 347 men and 437 women aged 35 to 90 years (mean +/- SD: 62 +/- 11 years) who participated in mass screening examinations in Wara village, Gifu, Japan. AV sclerosis was assessed by long- and short-axis 2-dimensional echocardiographic views and continuous-wave Doppler echocardiography. AV sclerosis was graded as follows: 0 = normal AV; 1 = increased echo density; 2 = thickening or calcific deposits > or = 3 mm; and 3 = same as 2 with mildly restricted motion (pressure gradient < 16 mm Hg). Lp(a) levels ranged from < 1 mg/dl to 153 mg/dl. The 25th, 50th, and 75th percentile values were 7, 16, and 28 mg/dl, respectively. Lp(a) levels were significantly higher in women than in men (p < 0.01), and did not increase significantly with age. The prevalence of AV sclerosis (grades 2 and 3) increased significantly with age (p < 0.001). AV sclerosis was present in 65 (36.1%) of 180 subjects with Lp(a) levels > or = 30 mg/dl and in 77 (12.7%) of 604 subjects with Lp(a) levels < 30 mg/dl (p < 0.001). There were no significant differences in the prevalence of AV sclerosis in terms of sex, blood pressure, or levels of total cholesterol, high-density lipoprotein cholesterol, triglycerides, or blood sugar. We conclude that increased serum levels of Lp(a), as well as aging, are closely related to AV sclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7484833     DOI: 10.1016/s0002-9149(99)80263-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  35 in total

1.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

Review 2.  Lp(a): Addressing a Target for Cardiovascular Disease Prevention.

Authors:  Nestor Vasquez; Parag H Joshi
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

Review 3.  Biomarkers of Calcific Aortic Valve Disease.

Authors:  Aeron Small; Daniel Kiss; Jay Giri; Saif Anwaruddin; Hasan Siddiqi; Marie Guerraty; Julio A Chirinos; Giovanni Ferrari; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-02-02       Impact factor: 8.311

Review 4.  Aortic valve sclerosis as a marker of active atherosclerosis.

Authors:  Kelley R Branch; Kevin D O'Brien; Catherine M Otto
Journal:  Curr Cardiol Rep       Date:  2002-03       Impact factor: 2.931

Review 5.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

Review 6.  Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.

Authors:  George Thanassoulis
Journal:  J Lipid Res       Date:  2015-12-18       Impact factor: 5.922

Review 7.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

8.  Smoothelin-positive cells in human and porcine semilunar valves.

Authors:  Massimo Cimini; Kem A Rogers; Derek R Boughner
Journal:  Histochem Cell Biol       Date:  2003-10-02       Impact factor: 4.304

9.  Brachial artery diameter has a predictive value in the improvement of flow-mediated dilation after aortic valve replacement for aortic stenosis.

Authors:  Munenori Takata; Eisuke Amiya; Masafumi Watanabe; Atsuko Ozeki; Aya Watanabe; Shuichi Kawarasaki; Tomoko Nakao; Yumiko Hosoya; Kansei Uno; Aya Saito; Takahide Murasawa; Minoru Ono; Ryozo Nagai; Issei Komuro
Journal:  Heart Vessels       Date:  2014-02-05       Impact factor: 2.037

10.  LP(a) phenotypes and levels in angiographically proven coronary heart disease patients and controls.

Authors:  K Luthra; S Vasisht; S Chhabra; K R Raju; D P Agarwal; S C Manchanda; L M Srivastava
Journal:  Indian J Clin Biochem       Date:  1998-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.